T
TAXIS Pharmaceuticals
TAXIS Pharmaceuticals is focused on the discovery and development of pharmaceuticals
About TAXIS Pharmaceuticals
TAXIS Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new generation of therapeutics to combat the global health crisis of antimicrobial resistance (AMR). Founded in 2009, the company originated from novel antimicrobial technologies discovered at Rutgers University by professors Daniel S. Pilch, Ph.D., and Edmond J. LaVoie, Ph.D. The leadership team includes Gregory G. Mario as President and CEO, who brings over two decades of life sciences experience, and Dr. Ernest Mario, who serves in board and venture partner capacities.
The company's core mission is to develop drugs that can overcome the defense mechanisms of multidrug-resistant (MDR) bacteria. Its business model centers on the research and development of proprietary drug candidates, with a strategy to seek partnerships and collaborations with larger pharmaceutical manufacturers for late-stage development and commercialization. Funding has been secured through a combination of venture capital, including Series A and B rounds, and significant non-dilutive grants from organizations like the National Institutes of Health (NIH) and CARB-X.
TAXIS's product pipeline features several drug candidates with distinct mechanisms of action that differ from antibiotics currently in clinical use. One of its key programs revolves around Efflux Pump Inhibitors (EPIs), which are designed to block the pumps that bacteria use to expel antibiotics, thereby restoring the effectiveness of existing drugs. Preclinical studies have shown these EPIs can work in synergy with at least 28 approved antibiotics against MDR pathogens like *Pseudomonas aeruginosa*. Another major focus is on FtsZ inhibitors. Its lead candidate, TXA709, targets the FtsZ protein, which is essential for bacterial cell division. TXA709 has completed a Phase I clinical trial for treating infections caused by Methicillin-Resistant *Staphylococcus aureus* (MRSA) and has received Qualified Infectious Disease Product (QIDP) designation from the FDA. Additionally, the company is developing Dihydrofolate Reductase Inhibitors (DHFRIs) to treat highly resistant gonorrhea by blocking an enzyme crucial for bacterial cell synthesis.
Source: Dealroom company dataNews
Open roles
TAXIS Pharmaceuticals in the South Brunswick ecosystem
The TAXIS Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
CARB-X
US National Institute of Allergy and Infectious Diseases
Series A1 investor entered at this stage
- ELEagles Ketch, LLC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TAXIS Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TAXIS Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

